3PC-023 Development and validation of a discriminative method for anthracyclines used in oncology by visible spectrometer

Background and importanceAnthracyclines are among the most used anticancer drugs in haematology–oncology, especially in the treatment of solid tumours and leukaemia. High performance liquid chromatography coupled with spectrometry is a well established method in the control of hospital chemotherapy preparations. However, it remains an expensive method, especially in low income countries. In recent years, UV visible spectrometry associated with partial least square discriminant regression has been used as a method for qualitative and quantitative analysis of drugs in the same therapeutic or physicochemical class.Aim and objectivesThe aim of the study was to develop a rapid spectrophotometric method for the discrimination of anthracyclines used in chemotherapy in a paediatric haematology–oncology centre by combining UV visible and partial least square analysis (PLS-DA).Material and methodsDifferent anthracyclines used routinely (daunorubicin, doxorubicin and epirubicin) were diluted with sodium chloride 0.5% at different concentrations. They were then analysed using a UV vis spectrometer at a wavelength ranging from 300 to 800 nm. Concentrations corresponding to an absorbance of